|
EP1718274A2
|
|
Controlled and sustained delivery of nucleic acid-based therapeutic agents
|
|
WO2005044236A1
|
|
Suspension delivery system for the sustained and controlled local release of pharmaceuticals
|
|
CN1842321A
|
|
Bioerodible sustained release drug delivery systems
|
|
EP1635787A2
|
|
Bioerodible sustained release drug delivery systems
|
|
TW200520761A
|
|
Steroid suspensions for intraocular use
|
|
US2005008695A1
|
|
Compositions and methods for delivering a biologically active agent
|
|
BRPI0406879A
|
|
sustained release drug release device
|
|
CN1741793A
|
|
Controlled release of highly soluble agents
|
|
US2004208910A1
|
|
Sustained release device and method for ocular delivery of adrenergic agents
|
|
US2004175410A1
|
|
Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
|
|
TW200500067A
|
|
Salts of codrugs and uses related thereto
|
|
CA2510296A1
|
|
Steroid compositions for intraocular use
|
|
US2004121014A1
|
|
Method for treating and/or preventing retinal diseases with sustained release corticosteroids
|
|
US2004115268A1
|
|
Systemic delivery of antiviral agents
|
|
AU2003287666A8
|
|
Systemic delivery of antiviral agents
|
|
AU2003301347A8
|
|
Methods for monitoring treatment of disease
|
|
US2004022853A1
|
|
Polymer-based, sustained release drug delivery system
|
|
CA2484632A1
|
|
Processes for forming a drug delivery device
|
|
AU2003234294A1
|
|
Device and method for treating conditions of a joint
|
|
US2003229390A1
|
|
On-stent delivery of pyrimidines and purine analogs
|
